$UPB

GRAY MICHAEL sold $5K of UPB

GRAY MICHAEL (CFO and COO) sold 853 shares of Upstream Bio, Inc. (UPB) at $6.10 on 2026-06-16.

Original reporting
SEC EDGAR · GRAY MICHAEL
Published Jun 17, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$UPB
Neutral
medium confidence
Mentioned
$UPB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UPBNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the CFO/COO, including date, share count, price, and post-transaction holdings.

02

Market read

Traders may monitor for clustering of insider activity, but this single small sale is unlikely to move the stock materially by itself.

03

What to watch

Insider sales can be driven by taxes, diversification, or personal liquidity; without follow-on buys/sales or larger transactions, the trading signal is weak.

Relevance 3/10Novelty 8/10Timing: today’s SEC Form 4 filing (filed 2026-06-17)

Background

This is an SEC Form 4 insider transaction disclosure for Upstream Bio, Inc. (UPB).

Company-level read

Ticker impact

$UPBNeutralMedium confidence
Context

Upstream Bio CFO/COO Michael Gray sold 853 shares in an open-market transaction on 2026-06-16 at $6.10/share, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction value (~$5.2k) is modest and does not indicate a company-level catalyst.

Market effects

No clear sector read-through from a small, single-insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as discretionary liquidity rather than bearish conviction, especially given the small size.

Key entities

  • Upstream Bio, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Michael Gray

    CFO and COO who sold 853 shares on 2026-06-16.

Related articles